Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes.
Böttcher M, Düngen HD, Corcea V, Donath F, Fuhr R, Gal P, Mikus G, Trenk D, Coenen M, Pires PV, Maschke C, Aliprantis AO, Besche N, Becker C. Böttcher M, et al. Among authors: aliprantis ao. Am J Cardiovasc Drugs. 2023 Mar;23(2):145-155. doi: 10.1007/s40256-022-00557-2. Epub 2023 Jan 12. Am J Cardiovasc Drugs. 2023. PMID: 36633816 Free PMC article. Clinical Trial.
Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults.
Phuah JY, Maas BM, Tang A, Zhang Y, Caro L, Railkar RA, Swanson MD, Cao Y, Li H, Roadcap B, Catchpole AP, Aliprantis AO, Vora KA. Phuah JY, et al. Among authors: aliprantis ao. Biomed Pharmacother. 2023 Dec 31;169:115851. doi: 10.1016/j.biopha.2023.115851. Epub 2023 Nov 14. Biomed Pharmacother. 2023. PMID: 37976891 Free article.
A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK-1654 in healthy Japanese adults.
Orito Y, Otani N, Matsumoto Y, Fujimoto K, Oshima N, Maas BM, Caro L, Aliprantis AO, Cox KS, Tokumaru O, Kodama M, Kudo H, Imai H, Uemura N. Orito Y, et al. Among authors: aliprantis ao. Clin Transl Sci. 2022 Jul;15(7):1753-1763. doi: 10.1111/cts.13290. Epub 2022 May 17. Clin Transl Sci. 2022. PMID: 35506164 Free PMC article. Clinical Trial.
Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis.
Maas BM, Lommerse J, Plock N, Railkar RA, Cheung SYA, Caro L, Chen J, Liu W, Zhang Y, Huang Q, Gao W, Qin L, Meng J, Witjes H, Schindler E, Guiastrennec B, Bellanti F, Spellman DS, Roadcap B, Kalinova M, Fok-Seang J, Catchpole AP, Espeseth AS, Stoch SA, Lai E, Vora KA, Aliprantis AO, Sachs JR. Maas BM, et al. Among authors: aliprantis ao. EBioMedicine. 2021 Nov;73:103651. doi: 10.1016/j.ebiom.2021.103651. Epub 2021 Nov 11. EBioMedicine. 2021. PMID: 34775220 Free PMC article.
A Phase 1 Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK-1654 in Healthy Adults.
Aliprantis AO, Wolford D, Caro L, Maas BM, Ma H, Montgomery DL, Sterling LM, Hunt A, Cox KS, Vora KA, Roadcap BA, Railkar RA, Lee AW, Stoch SA, Lai E. Aliprantis AO, et al. Clin Pharmacol Drug Dev. 2021 May;10(5):556-566. doi: 10.1002/cpdd.883. Epub 2020 Oct 30. Clin Pharmacol Drug Dev. 2021. PMID: 33125189 Clinical Trial.
A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults.
Aliprantis AO, Shaw CA, Griffin P, Farinola N, Railkar RA, Cao X, Liu W, Sachs JR, Swenson CJ, Lee H, Cox KS, Spellman DS, Winstead CJ, Smolenov I, Lai E, Zaks T, Espeseth AS, Panther L. Aliprantis AO, et al. Hum Vaccin Immunother. 2021 May 4;17(5):1248-1261. doi: 10.1080/21645515.2020.1829899. Epub 2020 Oct 29. Hum Vaccin Immunother. 2021. PMID: 33121346 Free PMC article. Clinical Trial.
Author Correction: Towards an arthritis flare-responsive drug delivery system.
Joshi N, Yan J, Levy S, Bhagchandani S, Slaughter KV, Sherman NE, Amirault J, Wang Y, Riegel L, He X, Rui TS, Valic M, Vemula PK, Miranda OR, Levy O, Gravallese EM, Aliprantis AO, Ermann J, Karp JM. Joshi N, et al. Among authors: aliprantis ao. Nat Commun. 2018 May 11;9(1):1954. doi: 10.1038/s41467-018-04346-x. Nat Commun. 2018. PMID: 29752435 Free PMC article.
Towards an arthritis flare-responsive drug delivery system.
Joshi N, Yan J, Levy S, Bhagchandani S, Slaughter KV, Sherman NE, Amirault J, Wang Y, Riegel L, He X, Rui TS, Valic M, Vemula PK, Miranda OR, Levy O, Gravallese EM, Aliprantis AO, Ermann J, Karp JM. Joshi N, et al. Among authors: aliprantis ao. Nat Commun. 2018 Apr 3;9(1):1275. doi: 10.1038/s41467-018-03691-1. Nat Commun. 2018. PMID: 29615615 Free PMC article.
Gut microbiota induce IGF-1 and promote bone formation and growth.
Yan J, Herzog JW, Tsang K, Brennan CA, Bower MA, Garrett WS, Sartor BR, Aliprantis AO, Charles JF. Yan J, et al. Among authors: aliprantis ao. Proc Natl Acad Sci U S A. 2016 Nov 22;113(47):E7554-E7563. doi: 10.1073/pnas.1607235113. Epub 2016 Nov 7. Proc Natl Acad Sci U S A. 2016. PMID: 27821775 Free PMC article.
44 results